<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332707</url>
  </required_header>
  <id_info>
    <org_study_id>3682-011</org_study_id>
    <secondary_id>2014-003304-73</secondary_id>
    <nct_id>NCT02332707</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)</brief_title>
  <official_title>A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, three-part, open-label trial of grazoprevir (MK-5172) (100 mg) and
      MK-3682 (300 mg or 450 mg), with either elbasvir (MK-8742) (50 mg) or MK-8408 (60 mg), and
      with or without ribavirin (RBV), in treatment-na√Øve (TN) and treatment-experienced (TE)
      cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) participants with chronic HCV
      genotype (GT) 1 or GT2 infection. Part A will consist of 8 arms to evaluate the safety of
      dose combinations. In Part B, participants will take 2 MK-3682B fixed dose combination (FDC)
      tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.) RBV (200 mg
      capsules; weight-based dosing). Participants who relapse following completion of therapy in
      Part A will be offered the option of retreatment with 16 weeks of MK-3682B with RBV in Part
      C (data obtained from Part C will not be used in the analysis of outcome measures).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A, study therapy will be administered as separate products, each taken q.d. by
      mouth. In Part B and Part C, participants will take 2 MK-3682B FDC tablets q.d. by mouth;
      each MK-3682B FDC tablet contains grazoprevir 50 mg + MK-3682 225 mg + MK-8408 30 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who had study drug discontinued due to an AE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR24)</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + elbasvir (50 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Part A: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + MK-8408 (60 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + elbasvir (50 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Part A: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected NC participants will take grazoprevir (100 mg) + MK-3682 (300 mg) + MK-8408 (60 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected NC participants will take grazoprevir (100 mg) + MK-3682 (450 mg) + elbasvir (50 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Part A/B: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, HCV GT1-infected NC participants will take grazoprevir (100 mg) + MK-3682 (450 mg) + MK-8408 (60 mg) once daily by mouth for 8 weeks. In Part B, HCV GT1-infected NC participants will take 2 MK-3682B tablets once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected NC participants will take grazoprevir (100 mg) + MK-3682 (450 mg) + elbasvir (50 mg) once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Part A/B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, HCV GT2-infected NC participants will take grazoprevir (100 mg) + MK-3682 (450 mg) + MK-8408 (60 mg) once daily by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 MK-3682B tablets once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 Part B: GT1 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected NC participants will take 2 MK-3682B tablets once daily by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected NC participants will take 2 MK-3682B tablets once daily by mouth for 8 weeks. Participants will also take RBV twice daily at a total daily dose of 800-1600 mg based on body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected NC participants will take 2 MK-3682B tablets once daily by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected C participants will take 2 MK-3682B tablets once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1-infected C participants will take 2 MK-3682B tablets once daily by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected C participants will take 2 MK-3682B tablets once daily by mouth for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected C participants will take 2 MK-3682B tablets once daily by mouth for 12 weeks. Participants will also take RBV twice daily at a total daily dose of 800-1600 mg based on body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2-infected C participants will take 2 MK-3682B tablets once daily by mouth for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>One grazoprevir 100 mg tablet (Part A), or two MK-3682B tablets each containing grazoprevir 50 mg (Part B), taken once daily by mouth.</description>
    <arm_group_label>1 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>2 Part A: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>6 Part A/B: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>7 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>8 Part A/B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT1 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_label>11 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>13 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <arm_group_label>16 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (16 weeks)</arm_group_label>
    <other_name>MK-5172</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682</intervention_name>
    <description>Two or three MK-3682 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or two MK-3682B tablets each containing MK-3682 225 mg (Part B), taken once daily by mouth.</description>
    <arm_group_label>1 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>2 Part A: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>5 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>6 Part A/B: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>7 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>8 Part A/B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT1 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_label>11 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>13 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <arm_group_label>16 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir</intervention_name>
    <description>One elbasvir 50 mg tablet (Part A), taken once daily by mouth.</description>
    <arm_group_label>1 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>3 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>5 Part A: GT1 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <arm_group_label>7 Part A: GT2 NC Grazoprevir+MK-3682+Elbasvir (8 weeks)</arm_group_label>
    <other_name>MK-8742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8408</intervention_name>
    <description>Six MK-8408 10 mg (60 mg total daily dose) capsules (Part A), or two MK-3682B tablets each containing MK-8408 30 mg (Part B), taken once daily by mouth.</description>
    <arm_group_label>2 Part A: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>4 Part A: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>6 Part A/B: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>8 Part A/B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT1 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_label>11 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>13 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <arm_group_label>16 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682B</intervention_name>
    <description>Two FDC tablets, each containing grazoprevir 50 mg + MK-3682 225 mg + MK-8408 30 mg (Part B), taken once daily by mouth.</description>
    <arm_group_label>6 Part A/B: GT1 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>8 Part A/B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>9 Part B: GT1 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_label>11 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>12 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (8 weeks)</arm_group_label>
    <arm_group_label>13 Part B: GT1 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>14 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks)</arm_group_label>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <arm_group_label>16 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (16 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin (RBV) 200 mg capsules taken twice-daily at a total daily dose of 800-1400 mg based on participant body weight.</description>
    <arm_group_label>10 Part B: GT2 NC Grazoprevir+MK-3682+MK-8408 (8 weeks) + RBV</arm_group_label>
    <arm_group_label>15 Part B: GT2 C Grazoprevir+MK-3682+MK-8408 (12 weeks) + RBV</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parts A and B:

          -  Previously untreated chronic HCV GT1 or GT2 with no evidence of non-typeable or mixed
             genotype infection

          -  Has HCV ribonucleic acid (RNA) &gt;= 10,000 IU/mL in peripheral blood at the time of
             screening

          -  Has cirrhosis of the liver (Part B only) or is non-cirrhotic (Part A and B)

          -  Is HCV treatment na√Øve (defined as no prior exposure to any interferon, ribavirin, or
             other approved or experimental HCV-specific direct-acting antiviral agent)

          -  Is of non childbearing potential or agrees to avoid becoming pregnant or impregnating
             a partner beginning at least 2 weeks prior to administration of the initial dose of
             study drug and either for 14 days after the last dose of study drug if not taking RBV
             or for 6 months after the last dose of study drug if taking RBV (or longer if
             dictated by local regulations). If not abstinent from heterosexual activity,
             participants in Part A must use 2 acceptable forms of barrier contraception whereas
             participants in Part B must use 2 acceptable forms of contraception which may include
             oral contraceptives

        Part B only:

          -  If coinfected with human immunodeficiency virus (HIV) is not currently on
             antiretroviral therapy (ART) and has no plans to initiate ART treatment while
             participating in this study OR has well controlled HIV on ART (the ART regimen must
             contain only the following antiretroviral medications: tenofovir, abacavir,
             lamivudine, emtricitabine, raltegravir, dolutegravir, and rilpivirine with no dose
             modifications or changes in drugs in the 4 weeks prior to study entry [Day 1])

          -  Has at least one viable antiretroviral regimen alternative beyond their current
             regimen in the event of HIV virologic failure and the development of anti-retroviral
             drug resistance

        Exclusion Criteria:

        Parts A, B, and C (unless noted otherwise):

          -  Has evidence of decompensated liver disease manifested by the presence of or history
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver disease

          -  For cirrhotics (Part B only), participants who are Child-Pugh Class B or C or who
             have a Pugh-Turcotte (CPT) score &gt;5, must be excluded

          -  Is coinfected with hepatitis B virus

          -  Is coinfected with HIV (Part A only)

          -  If coinfected with HIV (Part B only), has a history of opportunistic infection in the
             preceding 6 months prior to screening

          -  Has a history of malignancy &lt;=5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
             or carcinoma in situ; or is under evaluation for other active or suspected malignancy

          -  Has cirrhosis and has had liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  Has clinically-relevant drug or alcohol abuse within 12 months of screening

          -  Pregnant or breast-feeding, or expecting to conceive or donate eggs from at least 2
             weeks prior to Day 1 and 90 days after the last dose of study medication, or longer
             if dictated by local regulations

          -  Has any of the following conditions:

          -  organ transplants (including hematopoietic stem cell transplants) other than cornea
             and hair

          -  poor venous access that precludes routine peripheral blood sampling required for this
             trial

          -  has a history of gastric surgery (e.g., stapling, bypass) or history of malabsorption
             disorders (e.g., celiac sprue disease)

          -  current or history of any clinically significant cardiac abnormalities/dysfunction,
             including but not limited to: angina, congestive heart failure, myocardial
             infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy,
             significant arrhythmia, uncontrolled hypertension, a history of use of antianginal or
             anti-arrhythmic agents for cardiac conditions, prolonged ECG QTc interval (&gt;470 ms
             for males or &gt;480 ms for females by the Fridericia formula) at the screening visit,
             personal or family history of Torsade de pointes

          -  has chronic pulmonary disease, including but not limited to: clinically significant
             chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis,
             sarcoidosis

          -  has central nervous system (CNS) trauma requiring intubation, intracranial pressure
             monitoring, brain meningeal or skull surgery, or resulting in seizure, coma,
             permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF)
             leak. Prior brain hemorrhage and/or intracranial aneurysms (whether adequately
             repaired or not)

          -  has a current, or history of, seizure disorder unless seizure was &gt;10 years ago, a
             single isolated event, no history of or current use of anti-seizure medications
             prescribed, and a normal neurological examination is documented in trial files within
             6 months of Day 1

          -  Has a history of stroke or transient ischemic attack

          -  Has a history of a medical/surgical condition that resulted in hospitalization within
             the 3 months prior to enrollment, other than for minor elective procedures

          -  Has a medical/surgical conditions that may result in a need for hospitalization
             during the period of the study

          -  Has any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids, TNF antagonists, or other immunosuppressant drugs
             during the course of the trial

          -  has any condition, prestudy laboratory or ECG abnormality or history of any illness,
             which, in the opinion of the investigator, might confound the results of the study or
             pose additional risk in administering the study drugs to the subject

          -  has a life-threatening SAE during the screening period

          -  has evidence of history of chronic hepatitis not caused by HCV, including but not
             limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis,
             hemochromatosis, Wilson's disease, Œ±1-antitrypsin deficiency, alcoholic liver
             disease, and autoimmune hepatitis

          -  Part C only: is male whose female partner is/are pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0011)</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0029)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0005)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0014)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0038)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0004)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0034)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0049)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0031)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0020)</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0043)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0032)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0042)</name>
      <address>
        <city>Limerick</city>
        <state>Pennsylvania</state>
        <zip>19468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0027)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0047)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0033)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0041)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0015)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Czernik</last_name>
      <phone>48 22 4784324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Mateos Chacon</last_name>
      <phone>ensayos_clinicos@merck.com</phone>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 11, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
